Publications by authors named "Michael Garshick"
Background: Lipoprotein(a) [Lp(a)] is a driver of residual cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) decrease Lp(a) with significant heterogeneity in response. We investigated contributors to the heterogeneous response.
View Article and Find Full Text PDFPurpose Of Review: Cardiovascular disease (CVD) is a leading cause of preventable morbidity and mortality globally, and retinal imaging modalities (old and new) are being explored as noninvasive tools to predict latent atherosclerosis and cardiovascular disease. This review focuses on the emerging promise of fundoscopy, optical coherence tomography (OCT), and optical coherence tomography angiography (OCTA) in CVD prognostication.
Recent Findings: High-quality studies have established the utility of vessel-based parameters and discrete conditions diagnosable via fundoscopy in subclinical atherosclerosis detection or CVD prediction.
Article Synopsis
- Inflammatory bowel disease (IBD) can lead to a rare but serious condition called pericarditis, which causes inflammation of the heart's outer lining and is linked to significant health risks.
- A study identified that among over 3 million IBD patients from 2011 to 2020, about 0.28% experienced pericarditis, especially those with additional autoimmune conditions like lupus or rheumatoid arthritis.
- IBD patients who developed pericarditis had a higher risk of complications and inpatient mortality, highlighting the need for healthcare providers to recognize this connection and monitor at-risk patients closely.
Article Synopsis
- The skin and cardiovascular systems are interconnected, with various cardiovascular diseases linked to specific skin manifestations.
- Inflammatory skin conditions, like psoriasis, can lead to serious cardiovascular and metabolic health issues, while some cardiovascular medications may cause adverse skin reactions.
- This review emphasizes the importance of integrating dermatology and cardiology insights for effective diagnosis and management of patients experiencing both skin and cardiovascular problems.
The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives.
View Article and Find Full Text PDFThe strong association between lipoprotein (a) [Lp(a)] and atherosclerotic cardiovascular disease has led to considerations of Lp(a) being a potential target for mitigating residual cardiovascular risk. While approximately 20 % of the population has an Lp(a) level greater than 50 mg/dL, there are no currently available pharmacological lipid-lowering therapies that have demonstrated substantial reduction in Lp(a). Novel therapies to lower Lp(a) include antisense oligonucleotides and small-interfering ribonucleic acid molecules and have shown promising results in phase 2 trials.
View Article and Find Full Text PDFPurpose Of Review: Targeting traditional cardiovascular risk factors is effective in reducing recurrent cardiovascular events, yet the presence of residual cardiovascular risk due to underlying systemic inflammation is a largely unaddressed opportunity. This review aims to comprehensively assess the evolving role of colchicine as a therapeutic approach targeting residual inflammatory risk in the context of those with coronary artery disease (CAD).
Recent Findings: Inflammation plays a significant role in promoting atherosclerosis, and targeting anti-inflammatory pathways has the potential to decrease cardiovascular events.
Background: Cardiometabolic risk factors diabetes, obesity, and hypertension are highly prevalent and contribute to increased cardiovascular disease (CVD). Endothelial dysfunction precedes CVD development. The current study aimed to investigate the EC transcriptome among individuals with varying degree of cardiometabolic risk.
View Article and Find Full Text PDFArticle Synopsis
- JAK inhibitors are effective for treating certain skin conditions but carry a FDA warning due to potential risks, including cardiovascular events and infections, based on data primarily from rheumatoid arthritis patients.
- The study aimed to assess the risks associated with JAK inhibitors specifically in patients with dermatologic conditions, focusing on mortality and major adverse events.
- Data from phase 3 clinical trials were analyzed using systematic review methodologies to evaluate the safety of these treatments in dermatology, with results derived from 35 randomized trials.